Drug Profile
Research programme: anti-CD44 antibodies - Roche
Alternative Names: AR001; AR11BD-2E11-2; AR53A10.11; AR58A314.1; AR6BD-25; ARH460-16-2; ARH460-23Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ARIUS Research
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (IV)
- 24 Sep 2008 ARIUS Research has been acquired by Roche
- 03 Jun 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)